Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
NCT ID: NCT00890747
Last Updated: 2014-03-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
42 participants
Study Classification
INTERVENTIONAL
Study Start Date
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase I trial studies the side effects and the best dose of sunitinib malate in treating human immunodeficiency virus (HIV)-positive patients with cancer receiving antiretroviral therapy. Sunitinib malate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
NCT00387426
Accelerated Phase Chronic Myelogenous Leukemia
Acute Undifferentiated Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
+29 more
TERMINATED
PHASE2
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
NCT00451048
Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndromes
Myelodysplastic Syndromes
+1 more
COMPLETED
PHASE2
Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00398112
B-cell Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
COMPLETED
PHASE2
Sunitinib Malate in Treating Patients With Small Cell Lung Cancer
NCT00953459
Lung Cancer
TERMINATED
PHASE2
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
NCT00853125
Kidney Cancer
TERMINATED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
I. To determine the safety and to investigate the pharmacological interactions of administering sunitinib (sunitinib malate) in subjects with cancer who are also HIV positive on anti-retroviral regimens containing protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors.
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of sunitinib in treating non-acquired immunodeficiency syndrome (AIDS) defining cancers (NADCs) in these subjects.
II. To detect alterations in antiretroviral drug pharmacokinetics due to sunitinib.
III. To detect alterations in immune parameters, including total leukocyte count, cluster of differentiation (CD) 4 and viral load, during sunitinib therapy.
IV. To correlate variations in genes involved in sunitinib absorption, metabolism, and elimination, including cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4), cytochrome P450, family 3, subfamily A, polypeptide 5 (CYP3A5), ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1), and breast cancer resistance protein (ABCG2), with drug pharmacokinetics.
V. To explore the potential for pharmacological interactions between sunitinib and newer antiretroviral agents such as integrase and chemokine (C-C motif) receptor 5 (gene/pseudogene) (CCR5) inhibitors.
OUTLINE: This is a dose-escalation study.
Patients receive sunitinib malate orally (PO) daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days.
I. To determine the safety and to investigate the pharmacological interactions of administering sunitinib (sunitinib malate) in subjects with cancer who are also HIV positive on anti-retroviral regimens containing protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors.
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of sunitinib in treating non-acquired immunodeficiency syndrome (AIDS) defining cancers (NADCs) in these subjects.
II. To detect alterations in antiretroviral drug pharmacokinetics due to sunitinib.
III. To detect alterations in immune parameters, including total leukocyte count, cluster of differentiation (CD) 4 and viral load, during sunitinib therapy.
IV. To correlate variations in genes involved in sunitinib absorption, metabolism, and elimination, including cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4), cytochrome P450, family 3, subfamily A, polypeptide 5 (CYP3A5), ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1), and breast cancer resistance protein (ABCG2), with drug pharmacokinetics.
V. To explore the potential for pharmacological interactions between sunitinib and newer antiretroviral agents such as integrase and chemokine (C-C motif) receptor 5 (gene/pseudogene) (CCR5) inhibitors.
OUTLINE: This is a dose-escalation study.
Patients receive sunitinib malate orally (PO) daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Accelerated Phase Chronic Myelogenous Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Acute Undifferentiated Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Grade III Lymphomatoid Granulomatosis
Adult Langerhans Cell Histiocytosis
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Aggressive NK-cell Leukemia
AIDS-related Diffuse Large Cell Lymphoma
AIDS-related Diffuse Mixed Cell Lymphoma
AIDS-related Diffuse Small Cleaved Cell Lymphoma
AIDS-related Immunoblastic Large Cell Lymphoma
AIDS-related Lymphoblastic Lymphoma
AIDS-related Malignancies
AIDS-related Small Noncleaved Cell Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Chronic Eosinophilic Leukemia
Chronic Myelomonocytic Leukemia
Chronic Neutrophilic Leukemia
Chronic Phase Chronic Myelogenous Leukemia
Clear Cell Renal Cell Carcinoma
Cutaneous B-cell Non-Hodgkin Lymphoma
de Novo Myelodysplastic Syndromes
Essential Thrombocythemia
Extramedullary Plasmacytoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Hepatosplenic T-cell Lymphoma
HIV Infection
HIV-associated Hodgkin Lymphoma
Intraocular Lymphoma
Isolated Plasmacytoma of Bone
Light Chain Deposition Disease
Mast Cell Leukemia
Myelodysplastic Syndrome With Isolated Del(5q)
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Myeloid/NK-cell Acute Leukemia
Nodal Marginal Zone B-cell Lymphoma
Noncutaneous Extranodal Lymphoma
Osteolytic Lesions of Multiple Myeloma
Peripheral T-cell Lymphoma
Plasma Cell Neoplasm
Polycythemia Vera
Post-transplant Lymphoproliferative Disorder
Previously Treated Myelodysplastic Syndromes
Primary Myelofibrosis
Primary Systemic Amyloidosis
Progressive Hairy Cell Leukemia, Initial Treatment
Prolymphocytic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Mycosis Fungoides/Sezary Syndrome
Recurrent Renal Cell Cancer
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Hairy Cell Leukemia
Refractory Multiple Myeloma
Relapsing Chronic Myelogenous Leukemia
Stage IV Renal Cell Cancer
T-cell Large Granular Lymphocyte Leukemia
Testicular Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific
Waldenström Macroglobulinemia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (sunitinib malate)
Patients receive sunitinib malate PO daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
sunitinib malate
Intervention Type
DRUG
Given PO
pharmacological study
Intervention Type
OTHER
Correlative studies
laboratory biomarker analysis
Intervention Type
OTHER
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sunitinib malate
Given PO
Intervention Type
DRUG
pharmacological study
Correlative studies
Intervention Type
OTHER
laboratory biomarker analysis
Correlative studies
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
SU11248
sunitinib
Sutent
pharmacological studies
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Biopsy-proven solid tumor or hematological malignancy, including:
* Metastatic renal cell carcinoma
* A solid tumor malignancy, including an NADC or an AIDS-defining malignancy, if the subject has progressed following standard therapy and/or other curative options are not available
* A hematologic malignancy, except for blast-phase leukemia, for which effective standard therapy or other curative options are not available
* Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme linked immunosorbent assay (ELISA), positive western blotting (Western Blot), or other federally approved licensed HIV test, or a detectable blood level of HIV ribonucleic acid (RNA), or a positive anti-HIV antibody test
* On stable anti-retroviral therapy for at least 4 weeks with a protease inhibitor (PI)-based or non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen of at least three drugs, with no intention to change the regimen within 8 weeks after starting study drug
* Patients who are on NNRTI and ritonavir PI-based therapy are eligible and will be enrolled in the ritonavir PI-based group (Group 3)
* Patients who are on NNRTI and non-ritonavir PI-based therapy are eligible and will be enrolled in the non-ritonavir PI-based group (Group 2); NOTE: accrual to Group 2 will be closed upon approval of version 7.0 of the protocol
* Patients who are on a highly active antiretroviral therapy (HAART) combination that includes neither a PI nor a NNRTI agent are eligible and will be enrolled in the NNRTI-based group (Group 1)
* CD4 count \> 50 cells/uL
* Karnofsky performance status \> 60%
* Women of child-bearing potential must have a negative pregnancy test within 7 days before initiation of study drug dosing; post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; male and female subjects of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug; (Note: a woman of childbearing potential is one who is biologically capable of becoming pregnant; this includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives)
* Hemoglobin \>= 8.0 gm/dL
* Absolute neutrophil count (ANC) \>= 1500 cells/mm\^3
* Platelet count \>= 100,000 /mm\^3
* Creatinine within institutional normal limits or glomerular filtration rate (GFR) \> 60 mL/min/m\^2 (calculated by the Cockcroft-Gault equation), calculated as follows:
* For males = (140 - age\[years\]) x (body weight \[kg\])/ (72) x (serum creatinine \[mg/dL\])
* For females = 0.85 x male value
* Total bilirubin should be =\< 1.5 times upper limit of normal (ULN); if, however, the elevated bilirubin is felt to be secondary to indinavir therapy, then subjects will be allowed on protocol if total bilirubin =\< 3.5 mg/dL, provided that the direct bilirubin is =\< 1.5 times ULN; if the elevated bilirubin is felt to be secondary to atazanavir therapy, then subjects will be allowed on protocol without any limit on the total bilirubin if the direct bilirubin is =\< 1.5 times ULN
* Aspartate transaminase AST (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase ALT (serum glutamate pyruvate transaminase \[SGPT\]) \< 2.5 times the ULN; unless subjects have liver metastases, in which case both AST and ALT must be =\< 5 times ULN
* Life expectancy of 3 months or more
* Ability and willingness to give informed consent
* Subjects must in the opinion of the Investigator be capable of complying with this protocol
* Metastatic renal cell carcinoma
* A solid tumor malignancy, including an NADC or an AIDS-defining malignancy, if the subject has progressed following standard therapy and/or other curative options are not available
* A hematologic malignancy, except for blast-phase leukemia, for which effective standard therapy or other curative options are not available
* Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme linked immunosorbent assay (ELISA), positive western blotting (Western Blot), or other federally approved licensed HIV test, or a detectable blood level of HIV ribonucleic acid (RNA), or a positive anti-HIV antibody test
* On stable anti-retroviral therapy for at least 4 weeks with a protease inhibitor (PI)-based or non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen of at least three drugs, with no intention to change the regimen within 8 weeks after starting study drug
* Patients who are on NNRTI and ritonavir PI-based therapy are eligible and will be enrolled in the ritonavir PI-based group (Group 3)
* Patients who are on NNRTI and non-ritonavir PI-based therapy are eligible and will be enrolled in the non-ritonavir PI-based group (Group 2); NOTE: accrual to Group 2 will be closed upon approval of version 7.0 of the protocol
* Patients who are on a highly active antiretroviral therapy (HAART) combination that includes neither a PI nor a NNRTI agent are eligible and will be enrolled in the NNRTI-based group (Group 1)
* CD4 count \> 50 cells/uL
* Karnofsky performance status \> 60%
* Women of child-bearing potential must have a negative pregnancy test within 7 days before initiation of study drug dosing; post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; male and female subjects of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug; (Note: a woman of childbearing potential is one who is biologically capable of becoming pregnant; this includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives)
* Hemoglobin \>= 8.0 gm/dL
* Absolute neutrophil count (ANC) \>= 1500 cells/mm\^3
* Platelet count \>= 100,000 /mm\^3
* Creatinine within institutional normal limits or glomerular filtration rate (GFR) \> 60 mL/min/m\^2 (calculated by the Cockcroft-Gault equation), calculated as follows:
* For males = (140 - age\[years\]) x (body weight \[kg\])/ (72) x (serum creatinine \[mg/dL\])
* For females = 0.85 x male value
* Total bilirubin should be =\< 1.5 times upper limit of normal (ULN); if, however, the elevated bilirubin is felt to be secondary to indinavir therapy, then subjects will be allowed on protocol if total bilirubin =\< 3.5 mg/dL, provided that the direct bilirubin is =\< 1.5 times ULN; if the elevated bilirubin is felt to be secondary to atazanavir therapy, then subjects will be allowed on protocol without any limit on the total bilirubin if the direct bilirubin is =\< 1.5 times ULN
* Aspartate transaminase AST (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase ALT (serum glutamate pyruvate transaminase \[SGPT\]) \< 2.5 times the ULN; unless subjects have liver metastases, in which case both AST and ALT must be =\< 5 times ULN
* Life expectancy of 3 months or more
* Ability and willingness to give informed consent
* Subjects must in the opinion of the Investigator be capable of complying with this protocol
Exclusion Criteria
* Concurrent active opportunistic infection (OI)
* Acute treatment for an infection or other serious medical illness within 14 days prior to study entry
* Receipt of antineoplastic therapy, including investigational drug or standard treatment, within 2 weeks of study entry; must be able to demonstrate adequate recovery from prior therapy-related toxicities
* Major surgery or radiation within 3 weeks prior to study entry
* Concurrent treatment with medications, other than antiretroviral drugs used to treat HIV infection, that are known to inhibit or induce CYP3A4
* Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease
* Clinically significant cardiovascular disease, including uncontrolled hypertension (diastolic blood pressure \>= 100 mmHg despite optimal medical therapy) or unstable angina
* A myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident, transient ischemic attack, or pulmonary embolism within 6 months of study entry
* Abnormal left ventricular ejection fraction per institutional standards
* Ongoing ventricular cardiac dysrhythmias of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) grade \>= 2
* Subjects with a history of serious ventricular arrhythmia (ventricular tachycardia \[VT\] or ventricular fibrillation \[VF\] \>= 3 beats in a row)
* Serious cardiac arrhythmia requiring medication
* QTc interval \> 500 msec
* Psychiatric illness that would limit compliance with study requirements
* Pre-existing thyroid abnormality that cannot be maintained with medication to keep measures of thyroid stimulating hormone within the normal range
* Female subjects who are pregnant or breast-feeding
* Another severe and/or life-threatening medical disease
* Acute treatment for an infection or other serious medical illness within 14 days prior to study entry
* Receipt of antineoplastic therapy, including investigational drug or standard treatment, within 2 weeks of study entry; must be able to demonstrate adequate recovery from prior therapy-related toxicities
* Major surgery or radiation within 3 weeks prior to study entry
* Concurrent treatment with medications, other than antiretroviral drugs used to treat HIV infection, that are known to inhibit or induce CYP3A4
* Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease
* Clinically significant cardiovascular disease, including uncontrolled hypertension (diastolic blood pressure \>= 100 mmHg despite optimal medical therapy) or unstable angina
* A myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident, transient ischemic attack, or pulmonary embolism within 6 months of study entry
* Abnormal left ventricular ejection fraction per institutional standards
* Ongoing ventricular cardiac dysrhythmias of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) grade \>= 2
* Subjects with a history of serious ventricular arrhythmia (ventricular tachycardia \[VT\] or ventricular fibrillation \[VF\] \>= 3 beats in a row)
* Serious cardiac arrhythmia requiring medication
* QTc interval \> 500 msec
* Psychiatric illness that would limit compliance with study requirements
* Pre-existing thyroid abnormality that cannot be maintained with medication to keep measures of thyroid stimulating hormone within the normal range
* Female subjects who are pregnant or breast-feeding
* Another severe and/or life-threatening medical disease
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Deeken
Role: PRINCIPAL_INVESTIGATOR
AIDS Associated Malignancies Clinical Trials Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Site Status
Lombardi Comprehensive Cancer Center at Georgetown University
Washington D.C., District of Columbia, United States
Site Status
Northwestern University
Chicago, Illinois, United States
Site Status
AIDS - Associated Malignancies Clinical Trials Consortium
Rockville, Maryland, United States
Site Status
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Site Status
Washington University - Jewish
Saint Loius, Missouri, United States
Site Status
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site Status
Albert Einstein College of Medicine
The Bronx, New York, United States
Site Status
Case Western Reserve University
Cleveland, Ohio, United States
Site Status
Abramson Cancer Center of The University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site Status
Virginia Mason Medical Center
Seattle, Washington, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M Jr, Dowlati A, Little RF, Ivy SP, Deeken JF. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer. 2014 Apr 15;120(8):1194-202. doi: 10.1002/cncr.28554. Epub 2014 Jan 28.
Reference Type
RESULT
Rais R, Zhao M, He P, Xu L, Deeken JF, Rudek MA. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Biomed Chromatogr. 2012 Nov;26(11):1315-24. doi: 10.1002/bmc.2697. Epub 2012 Jan 18.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2012-02208
Identifier Type: REGISTRY
Identifier Source: secondary_id
AMC-061
Identifier Type: OTHER
Identifier Source: secondary_id
AMC-061
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-02208
Identifier Type: -
Identifier Source: org_study_id
NCT01727102
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
NCT00381641
COMPLETED
PHASE2
Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)
NCT00267748
COMPLETED
PHASE2
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
NCT00499135
COMPLETED
PHASE1
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
NCT00474994
COMPLETED
PHASE2
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
NCT00387335
COMPLETED
PHASE2
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
NCT00453310
COMPLETED
PHASE2
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
NCT00459875
COMPLETED
PHASE2
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
NCT00378911
COMPLETED
PHASE2
Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma
NCT01216657
TERMINATED
PHASE2
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
NCT06390826
ACTIVE_NOT_RECRUITING
PHASE2
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
NCT00478426
COMPLETED
PHASE2
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
NCT00428220
COMPLETED
NA
Sunitinib in Treating Patients With Relapsed Multiple Myeloma
NCT00514137
COMPLETED
PHASE2
Sunitinib in Treating Young Patients With Refractory Solid Tumors
NCT00387920
COMPLETED
PHASE1
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT01210053
UNKNOWN
PHASE2
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
NCT00397488
COMPLETED
PHASE2
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
NCT01118351
TERMINATED
PHASE2
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
NCT00397787
COMPLETED
PHASE2
Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00388037
COMPLETED
PHASE2
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
NCT00400569
COMPLETED
PHASE2
Sunitinib Non Small Cell Lung Cancer Patients Over 70
NCT00864721
COMPLETED
PHASE2
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
NCT00499473
COMPLETED
PHASE2
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
NCT00577382
COMPLETED
PHASE2